In conclusion, SRS(X-knife) with concurrent gifitinib therapy in NSCLC patients with symptomatic BMs, and EGFR mutation produced reliable improvement of KPS and survival. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.